Company Analysis
Sign in

Viking Therapeutics, Inc. (VKTX)

Nasdaq: VKTX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2014
Full chart Alerts Compare
Grade6.3
◀ Past 5.8● Present 7.0▶ Future 6.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$0.00
Net income-$360M-227.1%
Earnings per share$-3.19-215.8%
Operating cash flow-$279M-217.4%
Cash$166M+521.6%
Debtn/a
Shareholders’ equity$639M-27.4%
Shares, diluted112.7M+3.3%
Return on equity-56.3%
The recordfrom its filings
Filings in 202649
Newest filingNov 5 · SCHEDULE 13G/A
Annual reportFeb 11, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$22.3M
Insider buys, 12 months$100,000
Patents granted11
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $0.00Net income -$627MCash from operations -$463Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 29, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 28, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 28, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 25, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Sep 25, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Sep 24, 2026 · SEC EDGAR · Form 305B2
Form 305B2
Open the filing on sec.gov
Sep 23, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Sep 23, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton VKTX · research, not advice